Literature DB >> 20233707

N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.

Karin Jennbacken1, Tajana Tesan, Wanzhong Wang, Heléne Gustavsson, Jan-Erik Damber, Karin Welén.   

Abstract

Androgen-deprivation therapy (ADT) is the standard treatment for metastatic prostate cancer. One factor that has been implicated in the metastatic process is the cell adhesion molecule N-cadherin. In this study, we investigated if the expression of N-cadherin was influenced by androgen deprivation and was associated with metastasis in prostate cancer. The effect of androgen deprivation on N-cadherin expression was initially studied in androgen-dependent (AD) LNCaP and androgen-independent (AI) LNCaP-19 and PC-3 prostate cancer cell lines. Expression of N-cadherin increased in the absence of androgens in AI LNCaP-19 primary tumors and metastases and also in vitro, but not in AI PC-3 tumors, indicating a possible involvement of the androgen receptor in the regulation of N-cadherin. N-cadherin was absent in AD LNCaP tumors. No clear associations between N-cadherin and factors related with epithelial-mesenchymal transition or neuroendocrine differentiation could be established. In addition, N-cadherin was evaluated by immunohistochemistry in human prostate tumors. Expression of N-cadherin was more frequently found in tumors from patients treated with ADT than in tumors from patients with no prior hormonal treatment. N-cadherin expression was also associated with metastasis and Gleason score. Furthermore, increased N-cadherin was detected in prostate cancer biopsies already 3 months after initiation of ADT when tumors were in a regressed state. In summary the results indicate that androgen deprivation induces N-cadherin in prostate tumors. Moreover, N-cadherin was increased in castration-resistant tumors in patients with established metastases. This might indicate that castration induces molecular alterations in the tumor cells, resulting in a more invasive and metastatic phenotype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233707     DOI: 10.1677/ERC-10-0015

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  57 in total

Review 1.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

2.  N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.

Authors:  Sarah K Martin; Carmen A Banuelos; Marianne D Sadar; Natasha Kyprianou
Journal:  Mol Oncol       Date:  2014-11-15       Impact factor: 6.603

3.  Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.

Authors:  Benjamin M Johnson; Bently P Doonan; Faisal F Radwan; Azizul Haque
Journal:  Open Prost Cancer J       Date:  2010-01-01

Review 4.  The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.

Authors:  Rhonda L Bitting; Daneen Schaeffer; Jason A Somarelli; Mariano A Garcia-Blanco; Andrew J Armstrong
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

5.  Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.

Authors:  W-Y Chen; Y-C Tsai; M K Siu; H-L Yeh; C-L Chen; J J Yin; J Huang; Y-N Liu
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

6.  Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.

Authors:  Punit Saraon; Natasha Musrap; Daniela Cretu; George S Karagiannis; Ihor Batruch; Chris Smith; Andrei P Drabovich; Dominique Trudel; Theodorus van der Kwast; Colm Morrissey; Keith A Jarvi; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

7.  Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.

Authors:  Xiaohai Wang; Soo Ok Lee; Shujie Xia; Qi Jiang; Jie Luo; Lei Li; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

Review 8.  Adaptation or selection--mechanisms of castration-resistant prostate cancer.

Authors:  Yang Zong; Andrew S Goldstein
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

Review 9.  Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.

Authors:  Qu Deng; Dean G Tang
Journal:  Endocr Relat Cancer       Date:  2015-08-18       Impact factor: 5.678

10.  Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

Authors:  Tzu-Hua Lin; Soo Ok Lee; Yuanjie Niu; Defeng Xu; Liang Liang; Lei Li; Shauh-Der Yeh; Naohiro Fujimoto; Shuyuan Yeh; Chawnshang Chang
Journal:  J Biol Chem       Date:  2013-05-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.